‹
›
This content requires a premium subscription.
Please
log in
or
subscribe
to continue.
Keeping Current
SGLT2 Inhibitors and Other Classes of Therapies in HFpEF: Examining The Totality of Clinical Data
30
00:00:00
/ 00:31:53
30